ALX Oncology Holdings financials
$1.35−2.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$18.0M | -$19.0M | -$23.0M | -$22.5M | -$26.6M | -$31.8M | -$30.6M | -$32.6M | -$41.5M | -$37.8M | -$48.0M | -$53.3M |
| Net income | -$18.0M | -$17.9M | -$22.8M | -$22.1M | -$25.9M | -$30.8M | -$29.2M | -$30.7M | -$39.4M | -$35.6M | -$45.5M | -$51.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.13 | $-0.17 | $-0.42 | $-0.41 | $-0.49 | $-0.58 | $-0.54 | $-0.58 | $-0.76 | $-0.71 | $-0.93 | $-1.24 |
| EBITDA | -$18.2M | -$18.8M | -$22.9M | -$22.4M | -$23.3M | -$31.6M | -$30.4M | -$32.3M | -$41.3M | -$37.5M | -$48.0M | -$53.1M |
| Operating cash flow | -$16.1M | -$18.6M | -$19.0M | -$17.1M | -$23.4M | -$24.7M | -$32.0M | -$25.4M | -$26.6M | -$37.9M | -$39.7M | -$31.2M |
| Free cash flow | -$16.1M | -$18.7M | -$19.0M | -$17.1M | -$23.5M | -$24.7M | -$32.1M | -$25.5M | -$26.7M | -$38.1M | -$39.8M | -$32.5M |
| Diluted shares | 135.6M | 104.6M | 54.3M | 53.6M | 53.4M | 53.4M | 54.1M | 52.7M | 51.8M | 50.1M | 49.1M | 41.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.7M | $32.3M | $16.4M | $23.4M | $19.3M | $20.6M |
| Short-term investments | $115.5M | $108.0M | $28.4M | $37.2M | $60.0M | $77.2M |
| Total debt | $9.7M | $8.5M | $9.7M | $10.1M | $10.0M | $10.0M |
| Total assets | $160.8M | $178.3M | $59.0M | $82.7M | $95.3M | $120.9M |
| Total liabilities | $24.6M | $27.0M | $33.1M | $37.9M | $30.9M | $32.6M |
| Shareholders' equity | $136.2M | $151.3M | $26.0M | $44.8M | $64.4M | $88.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology